Clarivate Plc Stock Price, News & Analysis

On February 22, 2023, Clarivate Plc (NYSE: CLVT) and the KAIST Innovation Strategy and Policy Institute released a report analyzing the global innovation landscape of the AI chip industry. The report highlights a shift from mass-produced chips to specialized, mission-oriented processors due to rising demand for efficient data processing. Key findings indicate that the U.S. and Mainland China dominate AI chip patents, with the U.S. exhibiting higher patent quality. The report emphasizes collaboration between universities and industry for R&D innovation, proposing strategies for the future AI chip market.

On February 9, 2023, Clarivate (NYSE:CLVT) announced the integration of the Preprint Citation Index™ into the Web of Science™ platform. This new feature allows researchers to access nearly two million preprints from various reputable repositories such as arXiv, bioRxiv, and chemRxiv alongside peer-reviewed content. The index facilitates quicker research processes by linking preprints to final articles and displaying them on researchers' profiles. The initiative aims to enhance scientific collaboration and speed up advancements in global research challenges, further establishing Clarivate as a leader in academic publishing.

On February 7, 2023, Clarivate Plc (NYSE: CLVT) announced that it will release its financial results for the fourth quarter and full year 2022 on March 1, 2023, before market opening. Detailed financial information will be available on their investor website. A conference call and webcast will occur on the same day at 9:00 AM Eastern Time to discuss the results. Interested participants can access the live audio broadcast or join through the webcast link provided. Additionally, an audio replay will be available after the call until March 15, 2023.

Clarivate Plc (NYSE:CLVT) released a special investigation by BioWorld, examining the evolving understanding of obesity and the impact of new weight loss drugs. With an expected one billion people facing obesity by 2030, novel therapeutics, including GLP-1R agonists, offer promising alternatives to traditional weight loss methods. The report discusses the cultural complexities surrounding obesity, the limitations of using weight as a health indicator, and highlights that fitness may be more closely associated with health than weight itself. The findings suggest a shift in the medical community's perception of weight loss and overall health.

Clarivate Plc (NYSE:CLVT) recently released its 2023 Drugs to Watch report, marking its tenth anniversary. The report predicts over 70 drugs that may transform treatment for various conditions, including HIV and Parkinson's disease. Notably, 15 late-stage experimental treatments are expected to surpass $1 billion in annual sales within five years. The report also highlights promising developments in Mainland China, especially in oncology, with nine drugs forecasted to reach blockbuster status by 2030, supported by healthcare reforms under Healthy China 2030.

On January 3, 2023, Clarivate Plc (NYSE: CLVT) collaborated with the Chinese Academy of Sciences to release the 'Research Fronts 2022' report, detailing 165 significant research areas in sciences and social sciences. The report identifies 110 'hot' and 55 'emerging' fronts, with over a third related to COVID-19, focusing on topics like vaccine effectiveness. Utilizing the Essential Science Indicators database, the report provides insights into scientific trends, showcasing the US as the leader in research, while highlighting a narrowing gap with China.

Clarivate (NYSE: CLVT) announced the adoption of a Tax Benefits Preservation Plan to safeguard its U.S. net operating loss carryforwards exceeding $1 billion as of September 30, 2022. This plan aims to prevent an 'ownership change' that could limit its ability to utilize these tax benefits. The plan will expire on October 31, 2023, unless terminated earlier. Shareholders will receive one preferred share purchase right for each ordinary share, activating if any party acquires 4.9% or more of shares. The plan is similar to those by other companies with significant NOLs.

Clarivate Plc (NYSE: CLVT) announced a reduction in its Board of Directors from 14 to 11 members, with the resignation of directors Balakrishnan S. Iyer, Kosty Gilis, and Roxane White. This move aims to enhance corporate governance, with 10 of the 11 remaining directors being independent and 45% being female or racially diverse. Board Chair Andrew Snyder emphasized that a smaller board will improve decision-making efficiency and focus on long-term growth and shareholder value.